Literature DB >> 16439468

Dominant-negative TLR5 polymorphism reduces adaptive immune response to flagellin and negatively associates with Crohn's disease.

Andrew T Gewirtz1, Matam Vijay-Kumar, Steven R Brant, Richard H Duerr, Dan L Nicolae, Judy H Cho.   

Abstract

Crohn's disease (CD) is associated with elevated adaptive immunity to commensal microbes, with flagellin being a dominant antigen. In light of heightened awareness of the importance of innate immunity in regulating adaptive immunity and ambiguity as to the role of CD-associated immune responses in CD pathophysiology, we sought to determine whether natural acquisition of immune responses to flagellin were regulated by the innate immune flagellin receptor toll-like receptor 5 (TLR5) and determine whether persons carrying a recently defined common dominant-negative TLR5 polymorphism (TLR5-stop) might be protected from developing CD. Carriage rates of a recently defined dominant-negative TLR5 polymorphism (TLR5-stop) and levels of serum immunoreactivity to bacterial products were measured in inflammatory bowel disease patients, first-degree relatives, and unrelated controls. We observed that, in healthy subjects, persons carrying TLR5-stop had significantly lower levels of flagellin-specific IgG and IgA but had similar levels of total and LPS-specific Ig. Moreover, we observed that, among Jewish subjects, the carriage rate of TLR5-stop (in heterozygous state) was significantly less in CD patients, but not ulcerative colitis (UC) patients, compared with unaffected relatives and unrelated controls (5.4, 0.9, 6.0, and 6.5% for unaffected relatives, CD, UC, and unrelated Jewish controls, respectively, n = 296, 215, 185, and 416, respectively; P = 0.037 by likelihood calculation for CD vs. controls), indicating that TLR5-stop can protect persons of Jewish ethnicity against CD. We did not observe a significant association of TLR5-stop with CD in a non-Jewish cohort (11.1, 10.4, and 11.7% for unaffected relatives, CD, and UC, respectively; n = 841, 543, and 300 for unaffected relatives, respectively). These results demonstrate that natural acquisition of immune responses to flagellin are regulated by TLR5 and suggest that immune responses to flagellin are not merely associated with CD but rather promote the pathogenic response.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16439468     DOI: 10.1152/ajpgi.00544.2005

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  81 in total

Review 1.  Toll-like receptors in innate immunity and infectious diseases.

Authors:  Min-Hao Wu; Ping Zhang; Xi Huang
Journal:  Front Med China       Date:  2010-12-02

2.  Pattern recognition receptor and autophagy gene variants are associated with development of antimicrobial antibodies in Crohn's disease.

Authors:  Travis B Murdoch; Wei Xu; Joanne M Stempak; Carol Landers; Stephan R Targan; Jerome I Rotter; Mark S Silverberg
Journal:  Inflamm Bowel Dis       Date:  2012-01-24       Impact factor: 5.325

Review 3.  Novel susceptibility genes in inflammatory bowel disease.

Authors:  Colin Noble; Elaine Nimmo; Daniel Gaya; Richard K Russell; Jack Satsangi
Journal:  World J Gastroenterol       Date:  2006-04-07       Impact factor: 5.742

Review 4.  Toll like receptor-5: protecting the gut from enteric microbes.

Authors:  Matam Vijay-Kumar; Jesse D Aitken; Andrew T Gewirtz
Journal:  Semin Immunopathol       Date:  2007-12-07       Impact factor: 9.623

Review 5.  Inflammatory bowel disease, past, present and future: lessons from animal models.

Authors:  Atsushi Mizoguchi; Emiko Mizoguchi
Journal:  J Gastroenterol       Date:  2008-02-24       Impact factor: 7.527

Review 6.  Toll-like receptors in inflammatory bowel disease-stepping into uncharted territory.

Authors:  Avi Levin; Oren Shibolet
Journal:  World J Gastroenterol       Date:  2008-09-07       Impact factor: 5.742

7.  The role of the immune system in regulating the microbiota.

Authors:  Benjamin P Willing; Navkiran Gill; B Brett Finlay
Journal:  Gut Microbes       Date:  2010-03-04

Review 8.  Future biologic targets for IBD: potentials and pitfalls.

Authors:  Gil Y Melmed; Stephan R Targan
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-02       Impact factor: 46.802

9.  A history of recurrent positive selection at the toll-like receptor 5 in primates.

Authors:  Gabriela Wlasiuk; Soofia Khan; William M Switzer; Michael W Nachman
Journal:  Mol Biol Evol       Date:  2009-01-29       Impact factor: 16.240

Review 10.  Genetically engineered mouse models for studying inflammatory bowel disease.

Authors:  Atsushi Mizoguchi; Takahito Takeuchi; Hidetomo Himuro; Toshiyuki Okada; Emiko Mizoguchi
Journal:  J Pathol       Date:  2015-11-14       Impact factor: 7.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.